Role of anti-Her-2 therapy in bladder carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 12, 2010, Pages 1915-1920

  Marín, Álvaro Pinto ^a   Arranz, Enrique Espinosa ^a   Sánchez, Andrés Redondo ^a   Auñón, Pilar Zamora ^a   Barón, Manuel González ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Bladder cancer; Her 2; Lapatinib; Trastuzumab

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; LAPATINIB; PACLITAXEL; TRASTUZUMAB;

ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG RESPONSE; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UROGENITAL TRACT TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; PROGNOSIS; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 78649335094     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0850-7     Document Type: Article

References (31)

1. J Bellmunt M Hussain CP Dinney 2003 Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family Crit Rev Oncol Hematol 46 S85 S104 10.1016/S1040-8428(03)00067-2 12850530 (Pubitemid 36808975)
2. V Caner NS Turk F Duzcan, et al. 2008 No strong association between Her-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas Pathol Oncol Res 14 261 266 10.1007/s12253-008-9027-y 18415713
3. A Chakravarti K Winter CL Wu, et al. 2005 Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the radiation therapy oncology group Int J Radiat Oncol Biol Phys 62 2 309 317 1:CAS:528:DC%2BD2MXktFGhsrs%3D 15890569
4. NH Chow SH Chan TS Tzai, et al. 2001 Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder Clin Cancer Res 7 1957 1962 1:STN:280:DC%2BD3Mzpsleguw%3D%3D 11448910
5. CL Coogan CR Estrada S Kapur KJ Bloom 2004 Her-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder Urology 63 786 790 10.1016/j.urology.2003.10.040 15072912 (Pubitemid 38479440)
6. IJ Dahabreh H Linardou F Siannis, et al. 2008 Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials Oncologist 13 620 630 1:CAS:528: DC%2BD1cXpt1Cktbo%3D 10.1634/theoncologist.2008-0001 18586917 (Pubitemid 351904907)
7. R Gandour-Edwards PN Lara Jr AK Folkins, et al. 2002 Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95 1009 1015 1:CAS:528:DC%2BD38XntlSrtL0%3D 10.1002/cncr.10808 12209684 (Pubitemid 34925350)
8. MHA Hussain GR MacVicar DP Petrylak, et al. 2007 Trastuzumab, paclitaxel, carboplatin and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial J Clin Oncol 25 2218 2224 1:CAS:528: DC%2BD2sXnsVShtbs%3D 10.1200/JCO.2006.08.0994 17538166 (Pubitemid 46954646)
9. A Jemal R Siegel E Ward, et al. 2009 Cancer statistics, 2009 CA Cancer J Clin 59 4 225 249 10.3322/caac.20006 19474385
10. RE Jimenez M Hussain FJ Blanco, et al. 2001 Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors Clin Cancer Res 7 2440 2447 1:CAS:528:DC%2BD3MXmsVOmtLg%3D 11489824
11. Laé M, Couturier J, Oudard S et al. (2009) Assessing Her-2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol. doi: 10.1093/annonc/mdp488
12. Z Latif AD Walters I Dunn, et al. 2003 Her2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder Br J Cancer 83 1305 1309 10.1038/sj.bjc.6601245 (Pubitemid 37363421)
13. F Liedberg H Anderson G Chebil, et al. 2008 Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol Semin Ori 26 17 24 1:CAS:528:DC%2BD1cXlsVWqtw%3D%3D
14. P Lipponen M Eskelinen S Syrjanen, et al. 1991 Use of inmunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder Eur Urol 20 238 242 1:STN:280:DyaK38zmt1Kqtg%3D%3D 1688050
15. U Lonn S Lonn S Friberg, et al. 1995 Prognostic value of the amplification of c-erb-B2 in bladder carcinoma Clin Cancer Res 1 1189 1194 1:STN:280:DyaK1M%2FjsV2huw%3D%3D 9815911
16. H Matsubara Y Yamada K Naruse, et al. 2008 Potential for Her-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescence in situ hybridization Oncol Rep 19 57 63 18097576
17. LA McHugh M Kriajevska JK Mellon TR Griffiths 2007 Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens-evidence of scheduled-dependent synergy Urology 69 2 390 394 10.1016/j.urology.2006.12.003 17320695 (Pubitemid 46274953)
18. LA McHugh AE Sayan J Mejlvang, et al. 2009 Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells Int J Oncol 34 4 1155 1163 1:CAS:528:DC%2BD1MXkt1eis7k%3D 19287975
19. JK Mellon J Lunec C Wright, et al. 1996 C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value J Urol 155 321 326 1:STN:280:DyaK28%2FpsVGrsw%3D%3D 10.1016/S0022-5347(01)66653-9 7490879
20. JK Mellon J Lunec C Wright, et al. 1996 C-Erb-B2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value J Urol 155 1 321 326 1:STN:280:DyaK28%2FpsVGrsw%3D%3D 10.1016/S0022-5347(01)66653-9 7490879
21. AP Mitra RH Datar RJ Cote 2006 Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification J Clin Oncol 24 5552 5564 1:CAS:528:DC%2BD2sXmvVSqsA%3D%3D 10.1200/JCO.2006.08. 2073 17158541 (Pubitemid 46631336)
22. M Peyromaure F Scotte D Amsellen-Ouzana A Vieillefond S Oudard P Beuzeboc 2005 Trastuzumab in metastatic transitional cell carcinoma of the urinary tract: report on six patients Eur Urol 48 771 778 1:CAS:528:DC%2BD2MXht1CnsrbE 10.1016/j.eururo.2005.07.015 16126330 (Pubitemid 41495376)
23. PH Rajjayabun PE Keegan J Lunec JK Mellon 2005 ErbB receptor expression patterns in human bladder cancer Urology 66 1 196 200 1:STN:280: DC%2BD2MzmtFCntQ%3D%3D 10.1016/j.urology.2005.01.046 15992892 (Pubitemid 41002227)
24. K Sato M Moriyama S Mori, et al. 1992 An immunohistologic evaluation of C-erb-B-2 gene product in patients with urinary bladder carcinoma Cancer 70 2493 2498 1:STN:280:DyaK3s%2Fks1Sitg%3D%3D 10.1002/1097-0142(19921115)70:10<2493: :AID-CNCR2820701017>3.0.CO;2-K 1358427
25. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2 N Engl J Med 344 783 792 1:CAS:528:DC%2BD3MXisVGktrc%3D 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
26. M Underwood J Bartlett J Reeves, et al. 1995 C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 55 2422 2430 1:STN:280:DyaK2M3nslOhsQ%3D%3D 7757996
27. Van Cutsem E, Kang Y, Chung H et al. (2009) Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27:18 s (suppl; abstr LBA4509)
28. RT Vollmer PA Humphrey PE Swanson, et al. 1998 Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-Erb-B2, epidermal growth factor receptor and bcl-2 Cancer 82 715 723 1:STN:280:DyaK1c7jsF2ksA%3D%3D 10.1002/(SICI)1097-0142(19980215)82:4<715: :AID-CNCR15>3.0.CO;2-0 9477105 (Pubitemid 28090284)
29. K Wester A Sjostrom M de la Torre, et al. 2002 HER-2: a posible target for therapy of metastatic urinary bladder carcinoma Acta Oncol 41 282 288 10.1080/02841860260088836 12195748 (Pubitemid 34833053)
30. AC Wolff ME Hammond JN Schwartz, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145 1:CAS:528:DC%2BD2sXht1ejs7Y%3D 10.1200/JCO.2006.09.2775 17159189 (Pubitemid 350003059)
31. C Wülfing JH Machiels DJ Richel, et al. 2009 A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma Cancer 115 13 2881 2890 10.1002/cncr.24337 19399906